NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $17.99 -0.01 (-0.06 %) (As of 11/18/2018 01:32 AM ET)Previous Close$17.99Today's Range$17.83 - $18.3552-Week Range$11.95 - $26.10Volume700,156 shsAverage Volume1.02 million shsMarket Capitalization$588.49 millionP/E RatioN/ADividend YieldN/ABeta0.23 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts. Receive AMAG News and Ratings via Email Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AMAG Previous Symbol CUSIP00163U10 Webwww.amagpharma.com Phone617-498-3300 Debt Debt-to-Equity Ratio0.34 Current Ratio2.86 Quick Ratio2.72 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$609.95 million Price / Sales1.02 Cash FlowN/A Price / CashN/A Book Value$22.07 per share Price / Book0.82 Profitability EPS (Most Recent Fiscal Year)($5.71) Net Income$-199,220,000.00 Net Margins-6.98% Return on Equity-13.65% Return on Assets-6.12% Miscellaneous Employees762 Outstanding Shares34,540,000Market Cap$588.49 million OptionableOptionable AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions What is AMAG Pharmaceuticals' stock symbol? AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG." How were AMAG Pharmaceuticals' earnings last quarter? AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its earnings results on Thursday, November, 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.77) by $1.11. The specialty pharmaceutical company had revenue of $122.20 million for the quarter, compared to analyst estimates of $118.23 million. AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The business's revenue for the quarter was down 1.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($4.31) EPS. View AMAG Pharmaceuticals' Earnings History. When is AMAG Pharmaceuticals' next earnings date? AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for AMAG Pharmaceuticals. What price target have analysts set for AMAG? 10 analysts have issued 12 month price targets for AMAG Pharmaceuticals' shares. Their predictions range from $18.00 to $31.00. On average, they expect AMAG Pharmaceuticals' share price to reach $21.9650 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View Analyst Price Targets for AMAG Pharmaceuticals. What is the consensus analysts' recommendation for AMAG Pharmaceuticals? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AMAG Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AMAG Pharmaceuticals. What are Wall Street analysts saying about AMAG Pharmaceuticals stock? Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock: 1. According to Zacks Investment Research, "AMAG's Feraheme currently competes with IV iron replacement therapies including Venofer, Injectafer, Ferrlecit and their generic versions among others. Feraheme may also face competition from generic IV iron replacement products that could further limit sales. Currently, AMAG is involved in a patent litigation with Novartis’ generic arm, Sandoz, for Feraheme. However, in June 2018, the FDA accepted AMAGs new drug application for bremelanotide and the company is initiating programs to educate healthcare providers about diagnosing hypoactive sexual desire disorder. Loss estimates of the cmpany have remained stable ahead of the Q3 earnings. " (10/5/2018) 2. Cantor Fitzgerald analysts commented, ": We reiterate the Neutral rating and adjust our PT to $18 (from $17) for AMAG stock. With the commercial potential of Intrarosa still unproven and the approvability of bremelanotide unknown, we believe investors will view the Makena franchise as the most significant supporter of share price value, particularly now that the CBR business is being divested. We suppose a bullish outlook could prevail over the near- to intermediate-term if Makena holds its own and no evidence emerges that Intrarosa or bremelanotide could disappoint expectations. We believe that the set up for 2019 has to be decidedly positive for the stock to perform well over the next 12-18 months absent, of course, transformational business activities." (8/3/2018) Has AMAG Pharmaceuticals been receiving favorable news coverage? Headlines about AMAG stock have been trending neutral on Sunday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. AMAG Pharmaceuticals earned a daily sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of AMAG Pharmaceuticals' key competitors? Some companies that are related to AMAG Pharmaceuticals include Allakos (ALLK), Supernus Pharmaceuticals (SUPN), Madrigal Pharmaceuticals (MDGL), ACADIA Pharmaceuticals (ACAD), Myokardia (MYOK), Heron Therapeutics (HRTX), Xencor (XNCR), Prestige Consumer Healthcare (PBH), Pacira Pharmaceuticals (PCRX), Amicus Therapeutics (FOLD), Endocyte (ECYT), Global Blood Therapeutics (GBT), Opko Health (OPK), Reata Pharmaceuticals (RETA) and AnaptysBio (ANAB). Who are AMAG Pharmaceuticals' key executives? AMAG Pharmaceuticals' management team includes the folowing people: Dr. William K. Heiden, CEO, Pres & Director (Age 58)Mr. Edward H. Myles, Exec. VP & CFO (Age 46)Mr. Joseph D. Vittiglio, Exec. VP of Legal Affairs and Quality, Gen. Counsel & Sec. (Age 46)Dr. Julie Krop, Exec. VP of Devel. & Chief Medical Officer (Age 52)Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48) Who are AMAG Pharmaceuticals' major shareholders? AMAG Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Jackson Square Partners LLC (8.20%), FMR LLC (5.39%), Renaissance Technologies LLC (4.77%), Dimensional Fund Advisors LP (3.18%), Robeco Institutional Asset Management B.V. (2.89%) and Robeco Institutional Asset Management B.V. (2.89%). Company insiders that own AMAG Pharmaceuticals stock include Joseph Vittiglio, Julie Krop and William K Heiden. View Institutional Ownership Trends for AMAG Pharmaceuticals. Which institutional investors are selling AMAG Pharmaceuticals stock? AMAG stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., FMR LLC, Man Group plc, Clark Estates Inc. NY, TIAA CREF Investment Management LLC, Wells Fargo & Company MN, Foundry Partners LLC and Canada Pension Plan Investment Board. Company insiders that have sold AMAG Pharmaceuticals company stock in the last year include Joseph Vittiglio and William K Heiden. View Insider Buying and Selling for AMAG Pharmaceuticals. Which institutional investors are buying AMAG Pharmaceuticals stock? AMAG stock was bought by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, Acadian Asset Management LLC, Skandinaviska Enskilda Banken AB publ , Bridgeway Capital Management Inc., Royce & Associates LP, AXA, Matarin Capital Management LLC and Macquarie Group Ltd.. View Insider Buying and Selling for AMAG Pharmaceuticals. How do I buy shares of AMAG Pharmaceuticals? Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is AMAG Pharmaceuticals' stock price today? One share of AMAG stock can currently be purchased for approximately $17.99. How big of a company is AMAG Pharmaceuticals? AMAG Pharmaceuticals has a market capitalization of $588.49 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe. What is AMAG Pharmaceuticals' official website? The official website for AMAG Pharmaceuticals is http://www.amagpharma.com. How can I contact AMAG Pharmaceuticals? AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected] MarketBeat Community Rating for AMAG Pharmaceuticals (NASDAQ AMAG)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 318 (Vote Outperform)Underperform Votes: 418 (Vote Underperform)Total Votes: 736MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 11/18/2018 by MarketBeat.com StaffFeatured Article: What is systematic risk?